MELLIPHARM, s. r. o.Active
Key figures
Key figures
2025Balance sheet structure
Summary of annual reports2020–2025
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Balance sheet — assets | ||||||
| Total current assets | 238 121 | 248 083 | 369 580 | 412 338 | 363 664 | 447 301 |
| Total non-current assets | 54 059 | 47 469 | 43 329 | 37 131 | 73 484 | 73 140 |
| Total assets | 292 180 | 295 594 | 417 718 | 454 978 | 441 202 | 526 770 |
| Balance sheet — liabilities and equity | ||||||
| Total liabilities | 228 776 | 224 029 | 317 578 | 331 631 | 310 763 | 377 408 |
| Share capital | 5 000 | 5 000 | 5 000 | 5 000 | 5 000 | 5 000 |
| Retained earnings of previous periods | -13 754 | -4 346 | 3 815 | 32 390 | 55 597 | 62 689 |
| Profit for the year (equity) | 9 408 | 8 161 | 28 575 | 23 207 | 7 092 | 18 923 |
| Reserves and other equity | 62 750 | 62 750 | 62 750 | 62 750 | 62 750 | 62 750 |
| Total equity | 63 404 | 71 565 | 100 140 | 123 347 | 130 439 | 149 362 |
| Income statement | ||||||
| Revenue (net turnover) | 837 610 | 963 881 | 1 070 023 | 1 082 268 | 1 039 418 | 1 189 914 |
| Operating profit | 12 888 | 11 378 | 37 715 | 29 012 | 11 653 | 22 788 |
| EBITDA | 21 712 | 19 293 | 46 042 | 38 604 | 21 244 | 39 581 |
| Profit before income tax | 11 555 | 10 623 | 38 295 | 30 001 | 13 116 | 23 196 |
| Profit for the reporting year | 9 408 | 8 161 | 28 575 | 23 207 | 7 092 | 18 923 |
| Labour costs | 125 103 | 139 859 | 159 321 | 158 565 | 157 055 | 177 395 |
| Depreciation of non-current assets | 8 824 | 7 915 | 8 327 | 9 592 | 9 591 | 16 793 |
| Other indicators | ||||||
| Calculated dividends | — | 0 | 0 | 0 | 0 | 0 |
A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.
Documents in the Register of Financial Statements14
- 2025 Úč POD · 12 pp.
- 2025 Úč POD
- 2024 Oznámenie o dátume schválenia účtovnej závierky · 1 pp.
- 2024 Úč POD · 12 pp.
- 2024 Úč POD
- 2023 Oznámenie o dátume schválenia účtovnej závierky · 1 pp.
- 2023 Úč POD · 12 pp.
- 2023 Úč POD
- 2022 Oznámenie o dátume schválenia účtovnej závierky · 1 pp.
- 2022 Úč POD · 12 pp.
- 2022 Úč POD
- 2021 Oznámenie o dátume schválenia účtovnej závierky · 1 pp.
- 2021 Úč POD · 12 pp.
- 2021 Úč POD
Documents open directly on registeruz.sk (Ministry of Finance of the Slovak Republic).
Similar companies
Summary: MELLIPHARM, s. r. o.
Overview
MELLIPHARM, s. r. o. (IČO 46366296) is a limited liability company (s.r.o.). The company was incorporated in 2011 and has existed for 15 years. Registered office according to the register: Košice. Main activity according to the Statistical Office: ostatný nešpecializovaný maloobchod (SK NACE 4712). Size category by number of employees: 5–9 employees.
People
The statutory body has 2 members. According to the register, the company has one shareholder. The registered capital is 5 000 €.
Financial results
Revenue for 2025 was 1 189 914 €, up 14,5 % on the previous year (1 039 418 €). From 2020 to 2025, revenue grew by an average of 7,3 % per year. This is the highest revenue in the reported years (2020–2025). Net profit for 2025 was 18 923 € (1,6 % of revenue). The company was profitable in all 6 reported years. Personnel costs for 2025 were 177 395 €. At the end of 2025 the company had total assets of 526 770 € and equity of 149 362 € (equity ratio 28,4 %).
Sources and freshness
Company and people data come from the Register of Legal Entities (Statistical Office SR, CC BY 4.0) and financial statements from the Register of Financial Statements (Ministry of Finance SR); icoprofil.sk updates them daily. Data as of 30. 10. 2026. Changes, averages and ratios are calculated by icoprofil.sk from open data and are not an official assessment.